A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling

Jie Chen, Yimin Fang

Research output: Contribution to journalComment/debate

Abstract

Originally discovered as an anti-fungal agent, the bacterial macrolide rapamycin is a potent immunosuppressant and a promising anti-cancer drug. In complex with its cellular receptor, the FK506-binding protein (FKBP12), rapamycin binds and inhibits the function of the mammalian target of rapamycin (mTOR). By mediating amino acid sufficiency, mTOR governs signaling to translational regulation and other cellular functions by converging with the phosphatidylinositol 3-kinase (PI3K) pathway on downstream effectors. Whether mTOR receives mitogenic signals in addition to nutrient-sensing has been an unresolved issue, and the mechanism of action of rapamycin remained unknown. Our recent findings have revealed a novel link between mitogenic signals and mTOR via the lipid second messenger phosphatidic acid (PA), and suggested a role for mTOR in the integration of nutrient and mitogen signals. A molecular mechanism for rapamycin inhibition of mTOR signaling is proposed, in which a putative interaction between PA and mTOR is abolished by rapamycin binding. Collective evidence further implicates the regulation of the rapamycin-sensitive signaling circuitry by phospholipase D, and potentially by other upstream regulators such as the conventional protein kinase C, the Rho and ARF families of small G proteins, and calcium ions. As the mTOR pathway has been demonstrated to be an important anti-cancer target, the identification of new components and novel regulatory modes in mTOR signaling will facilitate the future development of diagnostic and therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)1071-1077
Number of pages7
JournalBiochemical Pharmacology
Volume64
Issue number7
DOIs
StatePublished - Oct 1 2002

Fingerprint

Sirolimus
Phosphatidic Acids
Nutrients
Antifungal agents
Tacrolimus Binding Protein 1A
Phosphatidylinositol 3-Kinase
Tacrolimus Binding Proteins
Food
Phospholipase D
Monomeric GTP-Binding Proteins
Macrolides
Second Messenger Systems
Immunosuppressive Agents
Mitogens
Protein Kinase C
Neoplasms

Keywords

  • Mammalian target of rapamycin (mTOR)
  • Phosphatidic acid
  • Phosphatidylinositol 3-kinase (PI3K)
  • Phospholipase D (PLD)
  • Rapamycin

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. / Chen, Jie; Fang, Yimin.

In: Biochemical Pharmacology, Vol. 64, No. 7, 01.10.2002, p. 1071-1077.

Research output: Contribution to journalComment/debate

@article{0a2cdc8c6dab4f65988de19f30b7f194,
title = "A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling",
abstract = "Originally discovered as an anti-fungal agent, the bacterial macrolide rapamycin is a potent immunosuppressant and a promising anti-cancer drug. In complex with its cellular receptor, the FK506-binding protein (FKBP12), rapamycin binds and inhibits the function of the mammalian target of rapamycin (mTOR). By mediating amino acid sufficiency, mTOR governs signaling to translational regulation and other cellular functions by converging with the phosphatidylinositol 3-kinase (PI3K) pathway on downstream effectors. Whether mTOR receives mitogenic signals in addition to nutrient-sensing has been an unresolved issue, and the mechanism of action of rapamycin remained unknown. Our recent findings have revealed a novel link between mitogenic signals and mTOR via the lipid second messenger phosphatidic acid (PA), and suggested a role for mTOR in the integration of nutrient and mitogen signals. A molecular mechanism for rapamycin inhibition of mTOR signaling is proposed, in which a putative interaction between PA and mTOR is abolished by rapamycin binding. Collective evidence further implicates the regulation of the rapamycin-sensitive signaling circuitry by phospholipase D, and potentially by other upstream regulators such as the conventional protein kinase C, the Rho and ARF families of small G proteins, and calcium ions. As the mTOR pathway has been demonstrated to be an important anti-cancer target, the identification of new components and novel regulatory modes in mTOR signaling will facilitate the future development of diagnostic and therapeutic strategies.",
keywords = "Mammalian target of rapamycin (mTOR), Phosphatidic acid, Phosphatidylinositol 3-kinase (PI3K), Phospholipase D (PLD), Rapamycin",
author = "Jie Chen and Yimin Fang",
year = "2002",
month = "10",
day = "1",
doi = "10.1016/S0006-2952(02)01263-7",
language = "English (US)",
volume = "64",
pages = "1071--1077",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling

AU - Chen, Jie

AU - Fang, Yimin

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Originally discovered as an anti-fungal agent, the bacterial macrolide rapamycin is a potent immunosuppressant and a promising anti-cancer drug. In complex with its cellular receptor, the FK506-binding protein (FKBP12), rapamycin binds and inhibits the function of the mammalian target of rapamycin (mTOR). By mediating amino acid sufficiency, mTOR governs signaling to translational regulation and other cellular functions by converging with the phosphatidylinositol 3-kinase (PI3K) pathway on downstream effectors. Whether mTOR receives mitogenic signals in addition to nutrient-sensing has been an unresolved issue, and the mechanism of action of rapamycin remained unknown. Our recent findings have revealed a novel link between mitogenic signals and mTOR via the lipid second messenger phosphatidic acid (PA), and suggested a role for mTOR in the integration of nutrient and mitogen signals. A molecular mechanism for rapamycin inhibition of mTOR signaling is proposed, in which a putative interaction between PA and mTOR is abolished by rapamycin binding. Collective evidence further implicates the regulation of the rapamycin-sensitive signaling circuitry by phospholipase D, and potentially by other upstream regulators such as the conventional protein kinase C, the Rho and ARF families of small G proteins, and calcium ions. As the mTOR pathway has been demonstrated to be an important anti-cancer target, the identification of new components and novel regulatory modes in mTOR signaling will facilitate the future development of diagnostic and therapeutic strategies.

AB - Originally discovered as an anti-fungal agent, the bacterial macrolide rapamycin is a potent immunosuppressant and a promising anti-cancer drug. In complex with its cellular receptor, the FK506-binding protein (FKBP12), rapamycin binds and inhibits the function of the mammalian target of rapamycin (mTOR). By mediating amino acid sufficiency, mTOR governs signaling to translational regulation and other cellular functions by converging with the phosphatidylinositol 3-kinase (PI3K) pathway on downstream effectors. Whether mTOR receives mitogenic signals in addition to nutrient-sensing has been an unresolved issue, and the mechanism of action of rapamycin remained unknown. Our recent findings have revealed a novel link between mitogenic signals and mTOR via the lipid second messenger phosphatidic acid (PA), and suggested a role for mTOR in the integration of nutrient and mitogen signals. A molecular mechanism for rapamycin inhibition of mTOR signaling is proposed, in which a putative interaction between PA and mTOR is abolished by rapamycin binding. Collective evidence further implicates the regulation of the rapamycin-sensitive signaling circuitry by phospholipase D, and potentially by other upstream regulators such as the conventional protein kinase C, the Rho and ARF families of small G proteins, and calcium ions. As the mTOR pathway has been demonstrated to be an important anti-cancer target, the identification of new components and novel regulatory modes in mTOR signaling will facilitate the future development of diagnostic and therapeutic strategies.

KW - Mammalian target of rapamycin (mTOR)

KW - Phosphatidic acid

KW - Phosphatidylinositol 3-kinase (PI3K)

KW - Phospholipase D (PLD)

KW - Rapamycin

UR - http://www.scopus.com/inward/record.url?scp=0036776168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036776168&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(02)01263-7

DO - 10.1016/S0006-2952(02)01263-7

M3 - Comment/debate

C2 - 12234610

AN - SCOPUS:0036776168

VL - 64

SP - 1071

EP - 1077

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 7

ER -